DCM Nouvelle Q1 FY27: consolidated PAT jumps as raw-material easing lifts OPM to ~17%
PAT +1620.6% YoY · revenue +13.78% · margins expanding
₹287.43 Cr
+13.78% YoY
₹27.53 Cr
+1620.6% YoY
9.52%
+8.9pp YoY
₹14.98
DCM Nouvelle's consolidated revenue for the quarter ended 30 June 2026 came in at ₹287.43 Cr, up 13.8% YoY (₹252.62 Cr) and 9.3% QoQ (₹263.04 Cr). Consolidated PAT of ₹27.53 Cr is up sharply from ₹1.60 Cr a year ago and ₹3.97 Cr last quarter, but both prior periods were near-breakeven, so the percentage move (1,621% YoY, 594% QoQ) is a low-base effect rather than a like-for-like scale-up — the more informative number is the margin: consolidated NPM expanded to 9.6% from 0.6% YoY and 1.5% QoQ, and OPM (EBITDA margin) to ~17.0% from 6.2% YoY and 6.7% QoQ. Standalone, which is the core textiles business and the larger driver, shows the same pattern at smaller amplitude: PAT of ₹31.45 Cr versus ₹6.66 Cr a year ago (+372% YoY) on revenue of ₹283.45 Cr (+13.5% YoY) — the smaller standalone growth rate versus consolidated's confirms the group number is amplified by a low base, not a materially different underlying story.
Q1 FY-2027 vs prior quarters
The margin move is a cost-line story: cost of materials consumed fell to 70.6% of consolidated revenue from 76.7% a year ago and 74.0% last quarter, the single largest driver of the PBT swing (consolidated PBT ₹38.13 Cr vs ₹3.84 Cr YoY and ₹6.10 Cr QoQ). Employee costs and other expenses were broadly stable as a share of revenue. The chemicals subsidiary, DCM Nouvelle Specialty Chemicals, remains loss-making — a segment loss of ₹3.96 Cr on just ₹3.98 Cr of segment revenue this quarter, which is why consolidated PAT (₹27.53 Cr) trails standalone PAT (₹31.45 Cr) by ₹3.92 Cr; the chemicals loss did narrow from ₹5.10 Cr a year ago, itself contributing to the consolidated YoY PAT growth off a lower base.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
No exceptional items this quarter (vs ₹37.47 Cr standalone impairment/labour-code charge in full FY26) — clean comparison base
EPS: standalone ₹16.84, consolidated ₹14.98 (not annualised) vs consolidated ₹1.20 a year ago
Management has issued no formal guidance or outlook on record for this business, and no analyst/street consensus estimate for this specific quarter could be located — DCM Nouvelle has minimal formal sell-side coverage (one tracked price target, no PAT estimates found), so vsStreet is unknown rather than inferred. No press release accompanied the filing beyond the board outcome letter. The board also convened the 10th AGM for 25 September 2026; the trading window closed 22 June 2026 ahead of this result and reopens post-disclosure. There were no exceptional items this quarter in either statement, making the YoY/QoQ comparisons clean of one-offs.
W1
Whether the material-cost relief (70.6% of revenue this quarter vs 76.7% YoY) holds into Q2 FY27 or reverses as input costs normalize
W2
Chemicals subsidiary trajectory — loss narrowed to ₹3.96 Cr from ₹5.10 Cr YoY but remains loss-making on ~₹4 Cr revenue
W3
Any capacity/outlook commentary at the 10th AGM on 25 September 2026, given no formal guidance is currently on record
Consolidated PAT of ₹27.53 Cr is 'profit for the period' before NCI; owners' share is ₹27.98 Cr offset by an NCI loss of ₹0.45 Cr. No exceptional items in current or year-ago quarter (both nil), so raw and adjusted YoY growth are identical — full FY26 had a one-off ₹37.47 Cr standalone impairment/labour-code hit, not present in any quarter compared here.